Corporate News Report: Chongqing Lummy Pharmaceutical Co., Ltd.
Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) experienced a neutral trading day on Thursday, 22 October 2026, concluding the 24‑hour window at 12:20 AM Central Europe with no change in price. The share is currently quoted at CNY 9.3 on major exchanges. With a circulating supply of 1.1 billion shares, the company’s market capitalisation stands at CNY 8.2 billion. In the past 24 hours, trading volume has totaled roughly CNY 2.2 billion of shares.
Recent Performance
- Month‑end gain: Since the close of the previous month, Chongqing Lummy has risen 40.65 %, underscoring a strong upward trajectory for the stock.
- Moving average context: The 200‑day simple moving average sits at CNY 5.36, indicating that the current price of CNY 9.3 lies well above the long‑term average.
- Historical highs and lows: The 52‑week high of CNY 9.76 was recorded on 16 October 2026, while the 52‑week low of CNY 4.30 occurred on 22 June 2026. The present price is comfortably close to the all‑time high, suggesting sustained investor confidence.
Peer Comparison (Last 24 Hours)
| Company | Symbol | 24‑Hour Change | Current Price | Market Cap | PE Ratio |
|---|---|---|---|---|---|
| Zhejiang Dali | 002214.SZ | 0 % | CNY 16.33 | CNY 9.8 bn | – |
| Beijing Yuanliu Hongyuan E | 603267.SS | 0 % | CNY 41.82 | CNY 9.8 bn | 41.37 |
| Jiangyin Jianghua Microele | 603078.SS | 0 % | CNY 25.28 | CNY 9.8 bn | 93.79 |
| Wintech‑nano Suzhou | 688757.SS | 0 % | CNY 24.24 | CNY 9.8 bn | – |
| Suzhou Sepax | 688758.SS | 0 % | CNY 23.09 | CNY 9.8 bn | 68.22 |
All of the peer companies reported a flat 0 % change over the same period, reflecting a broader market pause. Chongqing Lummy’s neutral movement, coupled with its recent 40 % month‑to‑month gain, positions it as a resilient performer amid a broader period of market stability.
Company Profile
Founded in 1999 and headquartered in Chongqing, Chongqing Lummy Pharmaceutical Co., Ltd. operates within China’s dynamic healthcare sector. The company’s product portfolio spans multiple therapeutic areas, including:
- Oncology, antibacterial, antiviral, and antifungal agents
- Liver disease adjuncts, endocrinology systems, and Chinese patent medicines
- Digestive, immune, blood, cardiovascular, and nervous system drugs
- Acid‑base balance and nutritional formulations
- Base large‑infusion products, American ginseng systems, and active pharmaceutical ingredients
This diversified product mix not only mitigates concentration risk but also aligns the company with the growing demand for both conventional and traditional Chinese medicine solutions. As the pharmaceutical industry continues to evolve, Chongqing Lummy’s comprehensive research, development, manufacturing, and distribution capabilities position it to capitalize on emerging therapeutic trends and regulatory opportunities.
Outlook
The company’s recent performance, strong market cap, and robust product pipeline suggest a solid foundation for continued growth. Investors should monitor key metrics such as earnings releases, clinical trial milestones, and regulatory approvals, which could further influence the stock’s trajectory. In the meantime, the current price remains a compelling entry point given the historical high proximity and the company’s established presence in multiple therapeutic domains.
